New CNS Study Awarded to GCT in USA
A randomized, double-blind, placebo-controlled phase II trial will be conducted at U.S. sites under GCT management. Study design assumes enrollment of patients with mild to moderate Alzheimer’s Disease, randomized in 3 treatment groups.
GCT team is conducting qualification of pre-selected professional Alzheimer’s Research Centers and will be ultimately responsible for crucial study activities, including regulatory support, local project management and monitoring.
Updated: December 24, 2018
Permanent link: https://2022.gctrials.com/news/new-cns-study-awarded-to-gct-in-usa/